Catalyst Pharmaceuticals (CPRX) Cost of Revenue (2019 - 2026)

Catalyst Pharmaceuticals' Cost of Revenue history runs 8 years deep, the most recent figure standing at $14.5 million for Q1 2026.

• Quarterly Cost of Revenue fell 19.18% year-over-year to $14.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.8 million (up 12.91% YoY) and the FY2025 annual result came in at $87.3 million, up 26.74% from the prior year.
• Cost of Revenue was $14.5 million for Q1 2026 at Catalyst Pharmaceuticals, down from $26.1 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $26.1 million in Q4 2025 and bottomed at $5.9 million in Q1 2022.
• A 5-year average of $15.1 million and a median of $14.5 million in 2026 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue soared 82.02% — and 2026, when it decreased 19.18%.
• Catalyst Pharmaceuticals' Cost of Revenue stood at $11.2 million in 2022, then jumped by 41.21% to $15.8 million in 2023, then jumped by 36.9% to $21.6 million in 2024, then increased by 20.47% to $26.1 million in 2025, then plunged by 44.48% to $14.5 million in 2026.
• Business Quant data shows CPRX's Cost of Revenue at $14.5 million in Q1 2026, $26.1 million in Q4 2025, and $22.7 million in Q3 2025.